Yarrow Bioscience (NASDAQ:YARW) Now Covered by Guggenheim

Guggenheim began coverage on shares of Yarrow Bioscience (NASDAQ:YARW) in a research note issued to investors on Friday, MarketBeat reports. The brokerage issued a buy rating and a $60.00 price objective on the stock.

Other equities analysts have also issued research reports about the stock. Wall Street Zen upgraded shares of Yarrow Bioscience to a “hold” rating in a research report on Saturday, August 22nd. TD Cowen assumed coverage on Yarrow Bioscience in a research note on Tuesday, July 28th. They issued a “buy” rating on the stock. Finally, BTIG Research began coverage on shares of Yarrow Bioscience in a report on Monday, August 3rd. They issued a “buy” rating and a $58.00 price target for the company. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $59.00.

Yarrow Bioscience Price Performance

Shares of NASDAQ YARW traded up $2.00 during midday trading on Friday, reaching $15.60. The stock had a trading volume of 229,754 shares, compared to its average volume of 164,478. Yarrow Bioscience has a 12-month low of $12.39 and a 12-month high of $46.95. The business’s 50-day simple moving average is $23.33. The company has a market cap of $41.65 million, a P/E ratio of -1.07 and a beta of 2.10.

Yarrow Bioscience (NASDAQ:YARW) last released its earnings results on Thursday, August 13th. The company reported ($3.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($3.33). Yarrow Bioscience had a negative return on equity of 84.40% and a negative net margin of 4,726.21%. The business had revenue of $0.10 million for the quarter, compared to analysts’ expectations of $0.20 million.

Institutional Investors Weigh In On Yarrow Bioscience

Several hedge funds have recently added to or reduced their stakes in the business. Braidwell LP purchased a new stake in shares of Yarrow Bioscience in the second quarter worth about $596,000. Susquehanna International Group LLP acquired a new stake in Yarrow Bioscience in the 2nd quarter worth about $77,000. Two Sigma Securities LLC purchased a new stake in Yarrow Bioscience during the 2nd quarter worth approximately $26,000. Nantahala Capital Management LLC purchased a new stake in Yarrow Bioscience during the 2nd quarter worth approximately $1,301,400,000. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Yarrow Bioscience during the second quarter valued at approximately $1,920,000. 83.78% of the stock is owned by hedge funds and other institutional investors.

About Yarrow Bioscience

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.